This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

What Do the Experts think about Mast's Upcoming Phase 3 Data for Vepoloxamer in Patients with Sickle Cell Disease?

Ticker(s): MSTX

Who's the expert?

A physician with significant experience treating sickle cell disease and an understanding of the EPIC trial.

Interview Questions
Q1.

What is your background treating sickle cell disease? How commonly do you see the disease? Are you seeing numbers of these patients change over time?

Added By: kcmckee
Q2.

What is currently your preferred method of treating sickle cell? Are there any others widely used? 

Added By: kcmckee
Q3.

Are there any upcoming treatment methods you are particularly excited about? How does the EPIC trial factor into your thoughts on sickle cell treatment? How likely do you think it is to reach the market? 

Added By: kcmckee
Q4.

What sort of factors are most important to you in prescribing a drug? Based on the Phase 1 and 2 data, do you think vepoloxamer could meet your criteria? How likely do you think it is to reach market?

Added By: kcmckee
Q5.

MSTX's drug aims to reduce the adhesiveness and fragility of blood cells. Does the science behind vepoloxamer seem like they could achieve this goal? Could this hypothetically treat all of the other problems associated with SSD or are there some that would definitely remain?

Added By: kcmckee
Q6.

A 2001 table featured in JAMA showed that vepoloxamer did not meet a a secondary endpoint on pain killer usage reduction- does this concern you going forward for Phase 3?

Added By: kcmckee

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.